Selank and Semax: Russian Nootropics Compared in Research

Two Russian Neuropeptides Compared

Selank and Semax were both developed at the Moscow Institute of Molecular Genetics and represent the Russian approach to synthetic neuropeptides: short, stable sequences that imitate or modulate endogenous signalling molecules. Although both show cognitive and anxiolytic effects, their molecular targets are fundamentally different.

Structural Comparison

1. Selank: TKPRPGP (7 amino acids) — tuftsin analogue. Primary targets: GABAergic system, serotonin transporter, BDNF.
2. Semax: MEHFPGP (7 amino acids) — ACTH(4-7)PGP analogue. Primary targets: BDNF induction, dopaminergic and serotonergic systems.

Both peptides have 7 amino acids and are administered intranasally — the similarity in length and route of administration leads to frequent confusion, although the sequences and mechanisms are different.

- 💡 Note

Anxiolysis vs. Cognition: When to Use Which Peptide?

In the research literature, Selank is primarily categorised as an anxiolytic: it reduces anxiety symptoms without sedation. Semax is more classified as a cognitive enhancer and neuroprotectant: it improves memory performance and protects neurons in ischaemic conditions. Both categorisations are simplified — the actual activity profiles overlap considerably.

Selank: Research Strengths

• Clearly demonstrated anxiolytic effect without dependency potential
• Immunomodulatory properties (tuftsin analogue)
• Well-tolerated safety profile in Russian studies

Semax: Research Strengths

• BDNF induction most strongly documented among neuropeptides
• Neuroprotective efficacy in cerebral ischaemia
• Approval in Russia — higher regulatory evidence level

Both compounds are not approved in Germany. Studien Peptide provides Selank and Semax as high-purity lyophilisates for authorised research laboratories.

- ⚗️ Research note